131 related articles for article (PubMed ID: 8569084)
1. Renal uptake of an 18-mer phosphorothioate oligonucleotide.
Oberbauer R; Schreiner GF; Meyer TW
Kidney Int; 1995 Oct; 48(4):1226-32. PubMed ID: 8569084
[TBL] [Abstract][Full Text] [Related]
2. Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy.
Rappaport J; Hanss B; Kopp JB; Copeland TD; Bruggeman LA; Coffman TM; Klotman PE
Kidney Int; 1995 May; 47(5):1462-9. PubMed ID: 7637275
[TBL] [Abstract][Full Text] [Related]
3. In vivo suppression of the renal Na+/Pi cotransporter by antisense oligonucleotides.
Oberbauer R; Schreiner GF; Biber J; Murer H; Meyer TW
Proc Natl Acad Sci U S A; 1996 May; 93(10):4903-6. PubMed ID: 8643501
[TBL] [Abstract][Full Text] [Related]
4. Distribution of the cellular uptake of phosphorothioate oligodeoxynucleotides in the rat kidney in vivo.
Carome MA; Kang YH; Bohen EM; Nicholson DE; Carr FE; Kiandoli LC; Brummel SE; Yuan CM
Nephron; 1997; 75(1):82-7. PubMed ID: 9031275
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
[TBL] [Abstract][Full Text] [Related]
6. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
[TBL] [Abstract][Full Text] [Related]
7. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate.
Sands H; Gorey-Feret LJ; Cocuzza AJ; Hobbs FW; Chidester D; Trainor GL
Mol Pharmacol; 1994 May; 45(5):932-43. PubMed ID: 8190109
[TBL] [Abstract][Full Text] [Related]
9. Distribution and excretion of a phosphorothioate oligonucleotide in rats with experimentally induced renal injury.
Masarjian L; de Peyster A; Levin AA; Monteith DK
Oligonucleotides; 2004; 14(4):299-310. PubMed ID: 15665597
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration.
Zhang R; Iyer RP; Yu D; Tan W; Zhang X; Lu Z; Zhao H; Agrawal S
J Pharmacol Exp Ther; 1996 Aug; 278(2):971-9. PubMed ID: 8768755
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.
Agrawal S; Temsamani J; Tang JY
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7595-9. PubMed ID: 1881900
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
Iversen PL; Mata J; Tracewell WG; Zon G
Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
[TBL] [Abstract][Full Text] [Related]
13. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of antisense oligonucleotides.
Agrawal S; Temsamani J; Galbraith W; Tang J
Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
[TBL] [Abstract][Full Text] [Related]
16. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
Temsamani J; Roskey A; Chaix C; Agrawal S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
[TBL] [Abstract][Full Text] [Related]
17. Distribution of (76)Br-labeled antisense oligonucleotides of different length determined ex vivo in rats.
Wu F; Yngve U; Hedberg E; Honda M; Lu L; Eriksson B; Watanabe Y; Bergström M; Långström B
Eur J Pharm Sci; 2000 May; 10(3):179-86. PubMed ID: 10767595
[TBL] [Abstract][Full Text] [Related]
18. Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion.
Soucy NV; Riley JP; Templin MV; Geary R; de Peyster A; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2006 Feb; 77(1):22-8. PubMed ID: 16496297
[TBL] [Abstract][Full Text] [Related]
19. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
